NCT07619092 Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy
| NCT ID | NCT07619092 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anders Jørgensen |
| Condition | Depression - Major Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 145 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 145 participants in total. It began in 2026-01-15 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to investigate whether administering flumazenil to reverse the effects of benzodiazepines and/or zopiclone during electroconvulsive therapy (ECT) can help reduce cognitive side effects without diminishing treatment effectiveness in hospitalized patients with depression. The investigators hypothesize that blockade of the GABA receptor with flumazenil will reduce cognitive side effects through improved seizures and a reduced need for electrical charge escalation during the ECT series. Cognitive side effects will be measured by the total score on the Screening for Cognitive Impairment in Psychiatry (SCIP) (primary outcome) at follow-up after completion of the ECT series. Furthermore, it is expected that the flumazenil strategy will reduce pre-treatment anxiety and improve patient satisfaction (secondary outcomes). In addition, flumazenil strategy is hypothesized to have beneficial effects on subjective cognitive complaints, autobiographical memory, and executive functioning (secondary outcomes). Finally, the flumazenil strategy is expected to be associated with more favorable structural and functional changes in executive functioning and memory-related brain networks after completion of the ECT series, which may, in turn, be linked to better overall cognition and autobiographical memory (secondary outcome measures). For exploratory purposes, the study will also examine longitudinal changes in depressive symptoms and cognitive outcomes from baseline to follow-up (tertiary outcomes). Investigators will compare two different pre-ECT benzodiazepine management strategies: 1. Flumazenil strategy (experimental): continued benzodiazepine and/or zopiclone use up until the time of the ECT session, followed by administration of flumazenil immediately prior to ECT 2. Benzodiazepine withholding strategy (treatment as usual): discontinuation of benzodiazepines and/or zopiclone prior to the ECT in accordance with standard clinical practice
Eligibility Criteria
Inclusion criteria: * Current depressive episode (unipolar or bipolar), corresponding to ICD-10 codes F31.3-5, F32 or F33. * Admitted at a study affiliated department in the Mental Health Services of the Capital Region of Denmark * Referred to ECT by the regular psychiatrist and has given consent to ECT * Currently receiving treatment with a benzodiazepine and/or zopiclone, at a minimum daily dose equivalent to 0.5 mg lorazepam. Exclusion criteria: * Involuntary treatment with ECT * Known gross abnormalities in brain structure deemed likely to influence cognitive functioning * Pregnancy or breast-feeding * Inability to read or understand Danish * Acute organic brain disease (e.g., delirium) influencing the ability to give informed consent * Any pre-existing condition associated with an increased risk of prolonged or uncontrollable seizures, including but not limited to epilepsy or alcohol- or benzodiazepine withdrawal states * Conditions associated with reduced metabolism of flumazenil (e.g., liver failure)
Contact & Investigator
Stella K. S. Lystlund, MSc in Psychology
✉ stella.klara.soerensdottir.lystlund@regionh.dk📞 + 45 21 35 40 55
Anders Jørgensen, MD, Ph.D.
PRINCIPAL INVESTIGATOR
Mental Health Services of the Capital Region
Frequently Asked Questions
Who can join the NCT07619092 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Depression - Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07619092 currently recruiting?
Yes, NCT07619092 is actively recruiting participants. Contact the research team at stella.klara.soerensdottir.lystlund@regionh.dk for enrollment information.
Where is the NCT07619092 trial being conducted?
This trial is being conducted at Frederiksberg, Denmark.
Who is sponsoring the NCT07619092 clinical trial?
NCT07619092 is sponsored by Anders Jørgensen. The principal investigator is Anders Jørgensen, MD, Ph.D. at Mental Health Services of the Capital Region. The trial plans to enroll 145 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.